Medication info
Telmisartan/Amlodipine/Atorvastatin Tablets 40/5/10 mg

Telmisartan/Amlodipine/Atorvastatin Tablets 40/5/10 mg

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›40mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium Micronized›10.4mg / 1 tablet
Manufacturer / importer
Jeil Pharmaceutical Co., Ltd.
Appearance
Oval, two-layer tablet consisting of a white layer and a light blue layer
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201801981 · Approved 2018.05.10 · Insurance code 645405320

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
This medicine should be taken once daily as 1 tablet with water, regardless of meals. It is recommended that it be taken at the same time each day (e.g., in the morning), if possible. This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, they may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Older adults: In patients 75 years of age or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia [type IIa]), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased to a maximum of 20 mg once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended starting dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, rosuvastatin Cmax increased approximately 2.1-fold and AUC approximately 1.2-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor patients closely.

Ingredients

Manufacturer
Jeil Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol level
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is for patients whose hypertension is not controlled by either amlodipine or telmisartan alone, and for those who must also take atorvastatin for treating hypercholesterolemia. The telmisartan/amlodipine combination is effective for blood pressure control in patients with essential hypertension. Atorvastatin is used as an adjunct to diet in various lipid disorders such as primary hypercholesterolemia, mixed hyperlipidemia, and familial hypercholesterolemia, lowering serum cholesterol and LDL cholesterol levels to delay the progression of atherosclerosis. Additionally, it improves cardiovascular health by reducing the risk of stroke, myocardial infarction, and vascular interventions in patients at high cardiovascular risk with elevated high-sensitivity C-reactive protein levels. Therefore, this medication is effectively used for the management of both hypertension and hyperlipidemia.

How to take

Adult dose

This medicine should be taken once daily as 1 tablet with water, regardless of meals. It is recommended that it be taken at the same time each day (e.g., in the morning), if possible. This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, they may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose be adjusted using the individual components (amlodipine or telmisartan). However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. In patients with severe renal impairment, however, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Older adults: In patients 75 years of age or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia [type IIa]), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which is adequate for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased to a maximum of 20 mg once daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended starting dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended starting dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, rosuvastatin Cmax increased approximately 2.1-fold and AUC approximately 1.2-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor patients closely.

Precautions

This medication can cause serious harm to the fetus during pregnancy, so if pregnancy is confirmed, it should be discontinued immediately. Individuals with allergies to the ingredients contained in this drug or similar medications, as well as those with certain liver or kidney diseases, should not take this medication. Particularly, those with severe liver disease, significant renal impairment, or a history of angioedema should not use this medication. Elderly patients or those with hypotension, hyperkalemia, or liver dysfunction should use this medication with caution. If symptoms of myalgia or muscle weakness occur, consult a doctor immediately, and in severe cases, discontinue use. This medication lowers blood pressure, which may cause dizziness or orthostatic hypotension, so caution is advised when driving or operating machinery. There may be interactions with other medications, so inform your physician or pharmacist if you are taking any other medications. Women who are breastfeeding should preferably not take this medication, and if unavoidable, should discontinue breastfeeding. Safety and efficacy in children and teenagers under 18 years have not been established, so it is not recommended for them. In case of overdose, symptoms like hypotension, dizziness, and arrhythmias may occur, and you should visit a medical institution immediately. This medication should be stored in a cool, dry place away from direct sunlight and out of reach of children.

Side effects

Peripheral edema, dyspepsia, frequent bowel movements, diabetes, dizziness, dry vesicular ear, urticaria, unstable angina, onychomycosis, lumbar spinal stenosis, ear discharge, vertigo, chronic gastritis, various gastrointestinal disorders, hiatal hernia, dysuria, rhinitis, discomfort in oropharynx, lung diseases, unspecified bowel disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, urinary frequency, tinnitus, hearing loss, halitosis, fatty liver, upper respiratory infection, back pain, sinusitis, diarrhea, pharyngitis, erectile dysfunction, increased sweating, flushing, fever, leg pain, malaise, palpitations, dependent edema, angina, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, sensory disturbances, involuntary muscle contractions, pain, fatigue, cough, hypertension, chest pain, nausea, headache, fatigue, nausea, abdominal pain, drowsiness, arrhythmia, bradycardia, peripheral ischemia, syncope, orthostatic hypotension, vasculitis, peripheral neuropathy, tremors, loss of appetite, constipation, dysphagia, pancreatitis, vomiting, gingival hyperplasia, allergic reactions, back pain, burning sensation, malaise, rigidity, weight gain, weight loss, arthralgia, osteoarthritis, muscle spasms, myalgia, sexual dysfunction, insomnia, neuroexcitability, depression, abnormal dreams, anxiety, depersonalization, dyspnea, epistaxis, angioedema, erythema multiforme, pruritus, rash, erythematous rash, papular rash, diplopia, ocular pain, urinary disorders, nocturia, dry mouth, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, headache, dizziness, constipation, nausea, abdominal pain, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, angioedema, hypersensitivity reactions, facial edema, lower limb edema, thrombocytopenia, increased uric acid, liver function abnormalities, liver disease, acute kidney injury, anemia, increased CPK, anaphylactic reactions, tendon pain, rhabdomyolysis, hematuria, edema, headache, dizziness, increased ALT, chest pain, cough, myalgia, increased CK, constipation, increased AST, asthenia, joint pain, fatigue, numbness, sensory disturbances, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, syncope, generalized pain, muscle spasms, gout, erectile dysfunction, acute kidney injury, oliguria, increased serum creatinine, hypotension, tachycardia, bradycardia, acute kidney injury, excessive peripheral vasodilation, reflex tachycardia, systemic hypotension, shock, non-cardiogenic pulmonary edema, headache, dizziness, asthenia, cough, nausea, fatigue, weakness, edema, lower limb edema, angioedema, pruritus, hypersensitivity reactions, increased sweating, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, increased blood pressure, worsening hypertension, hypotension, hyperkalemia, hypoglycemia, syncope, dyspepsia, diarrhea, urinary tract infection, erectile dysfunction, back pain, abdominal pain, muscle cramps, myalgia, bradycardia, eosinophilia, thrombocytopenia, increased uric acid, liver function abnormalities, liver disease, acute kidney injury, anemia, increased CPK, anaphylactic reactions, tendon pain, angioedema, vasculitis, dermatitis, rash, eczema, pruritus, angioedema, erythema multiforme, rash, erythematous rash, papular rash, Stevens-Johnson syndrome, eosinophilia with systemic symptoms of drug reaction syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, gynecomastia, depression, sleep disorders, interstitial lung disease, jaundice, hepatitis, transaminase elevation, severe myasthenia.

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a tightly closed container that blocks light. It is important to maintain storage temperature between 1 and 30 degrees Celsius at room temperature. Proper storage helps maintain the medication's effectiveness and safety.

Appearance and packaging

Appearance

Oval, two-layer tablet consisting of a white layer and a light blue layer

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.